Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03592472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 30, 2024 to Dec 30, 2026 Completion date: Jun 30, 2025 to Jun 30, 2028v20 Show 1 more changeShow less
    • Completion date: Jun 30, 2025 to Jun 30, 2028
  2. Primary completion date: Jun 30, 2023 to Dec 30, 2024 Completion date: Jun 30, 2023 to Jun 30, 2025v19 Show 1 more changeShow less
    • Completion date: Jun 30, 2023 to Jun 30, 2025
  3. Primary and study completion dates: Jun 30, 2022 to Jun 30, 2023v18
  4. Trial status: Active, Not Recruiting to Recruiting Study sites: 36 to 38 · Primary and study completion dates: Jan 17, 2022 to Jun 30, 2022v17 Show 2 more changesShow less
    • Study sites: 36 to 38
    • Primary and study completion dates: Jan 17, 2022 to Jun 30, 2022
  5. Re-verified, no change to tracked fieldsv16
Show 14 earlier versionsHide 14 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 36 of 36 sitesv15 Show 1 more changeShow less
    • Site details revised at 36 of 36 sites
  2. Study sites: 27 to 36v14
  3. Study sites: 26 to 27v13
  4. Study sites: 25 to 26v12
  5. Study sites: 18 to 25v11
  6. Study sites: 15 to 18v10
  7. Site details revised at 1 of 15 sitesv9
  8. Site details revised at 4 of 15 sitesv8
  9. Study sites: 12 to 15v7
  10. Study sites: 8 to 12v6
  11. Study sites: 3 to 8v5
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3v4 Show 1 more changeShow less
    • Study sites: 0 to 3
  13. Re-verified, no change to tracked fieldsv3
  14. Study title expanded, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Trial Details
NCT Number NCT03592472
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Renal Cell Carcinoma
Enrollment 413 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov